Atlantica is reaffirming its guidance for 2022 and continues to target Adjusted EBITDA of between $810 million and $870 million and CAFD of between $230 million and $250 million.
Raymond James Maintains Outperform on Abbott Laboratories, Lowers Price Target to $143
Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $150 to $143.
